Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Editorial
Nature Biotechnology 26, 137 (1 February 2008) | doi:10.1038/nbt0208-137
Raising the game
Abstract
This decade has been a disappointment in terms of the number of drugs approved each year by the US Food and Drug Administration (FDA). But 2007 will go down in history as the worst for 25 years, with only 19 new molecular entities (NMEs) registered for marketing.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
